Q2 Revenue Up 4% but Profit Halves as AI Spending Bites; Guidance Set
DOCS sits 94% above its 52-week low of $17.15.
Summary
Doximity posted Q2 FY2027 revenue of $174.5 million, up 4% from $168.5 million a year ago, but net income fell to $34.7 million from $62.1 million as AI investment and stock-based compensation surged. Adjusted EBITDA dropped 12% to $88.9 million, cutting the margin to 50.9% from 59.8%, and non-GAAP diluted EPS came in at $0.36 versus $0.45, while reported EPS was 18 cents. The top line is decelerating sharply from the 7% growth reported in Q1 FY2027, and the profit decline extends the pattern from last quarter when net income fell 54%. Management guided Q3 revenue to $195-196 million and full-year FY2027 revenue to $678-683 million with adjusted EBITDA of $317-325 million. CEO Jeff Tangney noted more than 190 health systems have purchased the AI suite, but the margin compression is the number traders will focus on.
At the time of this announcement, DOCS was trading at $33.20 on NYSE in the Technology sector, with a market capitalization of approximately $5.9B. The 52-week trading range was $17.15 to $66.11. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: BusinessWire.